Dukosi Ltd. Recognized with Frost & Sullivan’s 2023 Global Market Leadership Award for Revolutionizing the Battery Cell Monitoring Industry

Dukosi is a pioneering developer of cell monitoring and battery management technology, offering cutting-edge solutions for…

AFRICA OIL ANNOUNCES RESULTS OF SHARE BUYBACK PROGRAM

VANCOUVER, BC, Jan. 22, 2024 /CNW/ – (TSX: AOI) (Nasdaq-Stockholm: AOI) – Africa Oil Corp. (“Africa Oil”, or the “Company”) is pleased…

AFRICA OIL ANNOUNCES FINAL APPROVAL FOR AN INCREASE OF ITS INTEREST IN THE ORANGE BASIN BLOCK 3B/4B

VANCOUVER, BC, Jan. 22, 2024 /CNW/ – (TSX: AOI) (Nasdaq-Stockholm: AOI) – Africa Oil Corp. ( “Africa Oil”, or the “Company”) is…

House of Rohl® Welcomes New Brands and Expands Luxury Offerings for Endless Design Possibilities at IDS Toronto 2024

New brand introductions and latest launches reinforce the House of Rohl brand commitment to artistry, curation…

Haivision Announces Results for the Three Months and Full Year Ended October 31, 2023

Haivision continues to increase gross margins, improves operational efficiency while delivering 11.3% year over year revenue…

Galaxy Asset Management: December 2023 Month End AUM

NEW YORK, Jan. 17, 2024 /CNW/ – Galaxy Digital Holdings Ltd. (TSX: GLXY) (“Galaxy”) announced that its affiliate, Galaxy Asset…

Removing barriers to build more homes, faster in Guelph, Ontario

GUELPH, ON, Jan. 12, 2024 /CNW/ – Right now, in communities across the country, building the housing we…

Intact Financial Corporation provides update on catastrophe events in the fourth quarter

TORONTO, Jan. 12, 2024 /CNW/ – Intact Financial Corporation (TSX: IFC) today provided an update on catastrophe losses…

BLACK SWAN GRAPHENE ANNOUNCES DEVELOPMENT AGREEMENT BETWEEN NERD AND ROGER BULLIVANT, A VINCI GROUP COMPANY

TORONTO, Jan. 9, 2024 /CNW/ – Black Swan Graphene Inc. (“Black Swan“) (or the “Company“) (TSXV: SWAN) (OTCQB:…

Menarini Group and Insilico Medicine Enter Global Exclusive License Agreement for Novel KAT6 Inhibitor for Potential Breast Cancer Treatment and Other Oncology Indications

KAT6 is an emerging target in hormone sensitive breast tumors and other cancers. Overexpression of KAT6A/B correlates…